AstraZeneca announces FluMist Quadrivalent approved and available in Canada; Sinovac gets CFDA approval to start clinical trials of varicella vax;

> AstraZeneca ($AZN) Canada announced the approval and availability of FluMist Quadrivalent. Release

> Beijing-based Sinovac Dalian ($SVA) got approval from the China FDA to begin clinical trials of its varicella vaccine. Release

> Indian Immunologicals announced that its new $38 million facility to produce human and animal vaccines has begun operations. Story

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.